Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


20.11.2017

1 Am J Clin Pathol
1 Am J Pathol
2 BMC Cancer
4 Br J Cancer
1 Cancer Res
2 Clin Cancer Res
7 Eur Urol
1 J Magn Reson Imaging
9 J Urol
2 Nat Rev Urol
3 Oncol Rep
2 PLoS One
4 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. BAENA-DEL VALLE JA, Zheng Q, Hicks JL, Fedor H, et al
    Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides.
    Am J Clin Pathol. 2017;148:398-415.
    PubMed     Text format     Abstract available


    Am J Pathol

  2. KNUUTTILA M, Mehmood A, Huhtaniemi R, Yatkin E, et al
    Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.
    Am J Pathol. 2017 Nov 7. pii: S0002-9440(17)30537.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. TSAI HK, Lehrer J, Alshalalfa M, Erho N, et al
    Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    BMC Cancer. 2017;17:759.
    PubMed     Text format     Abstract available

  4. CINDOLO L, Natoli C, De Nunzio C, De Tursi M, et al
    Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
    BMC Cancer. 2017;17:753.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. LI P, Chen J, Kashiwagi E, Mizushima T, et al
    The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  6. NOBLE AR, Maitland NJ, Berney DM, Rumsby MG, et al
    Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  7. TRIGGIANI L, Mazzola R, Magrini SM, Alongi F, et al
    Reply to 'Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''.
    Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    

  8. BRAVO I
    Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'.
    Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    Cancer Res

  9. MURPHY SJ, Kosari F, Karnes RJ, Nasir A, et al
    Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.
    Cancer Res. 2017;77:6157-6167.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
    Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
    PubMed     Text format     Abstract available

  11. ZHANG W, Liu B, Wu W, Li L, et al
    Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
    PubMed     Text format     Abstract available


    Eur Urol

  12. TOMBAL B
    Assembling the Puzzle of Advanced Prostate Cancer: Lessons from GETUG-AFU 15.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30968.
    PubMed     Text format    

  13. RAMEY SJ, Agrawal S, Abramowitz MC, Moghanaki D, et al
    Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30900.
    PubMed     Text format     Abstract available

  14. AGGARWAL R
    Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30967.
    PubMed     Text format    

  15. CUCCHIARA V, Cooperberg MR, Dall'Era M, Lin DW, et al
    Genomic Markers in Prostate Cancer Decision Making.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30975.
    PubMed     Text format     Abstract available

  16. LAVORGNA G, Montorsi F, Salonia A
    Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30973.
    PubMed     Text format    

  17. LAMB AD, Bryant RJ, Camilleri P, Hamdy FC, et al
    Orient Expression: Solving the Mystery of Asian Prostate Cancer?
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30969.
    PubMed     Text format    

  18. MARTINI A, Gupta A, Cumarasamy S, Tewari AK, et al
    Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. In p
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30974.
    PubMed     Text format    


    J Magn Reson Imaging

  19. GIGANTI F, Gambarota G, Moore CM, Robertson NL, et al
    Prostate cancer detection using quantitative T2 and T2 -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillance.
    J Magn Reson Imaging. 2017 Nov 14. doi: 10.1002/jmri.25891.
    PubMed     Text format     Abstract available


    J Urol

  20. PISHGAR F, Ebrahimi H, Moghaddam SS, Fitzmaurice C, et al
    Global, Regional and National Burden of Prostate Cancer, 1990 - 2015: Results from the Global Burden of Disease Study 2015.
    J Urol. 2017 Nov 9. pii: S0022-5347(17)77883-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  21. PENSON DF
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:1200.
    PubMed     Text format    

  22. MOREY AF
    Re: Radiation-Induced Complex Anterior Urinary Fistulation for Prostate Cancer: A Retrospective Multicenter Study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS).
    J Urol. 2017;198:1201-1203.
    PubMed     Text format    

  23. TANEJA SS
    Re: Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    J Urol. 2017;198:1208-1211.
    PubMed     Text format    

  24. TANEJA SS
    Re: Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Urol. 2017;198:1209-1210.
    PubMed     Text format    

  25. TANEJA SS
    Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    J Urol. 2017;198:1210-1211.
    PubMed     Text format    

  26. ATALA A
    Re: The Metabolic Co-Regulator PGC1alpha Suppresses Prostate Cancer Metastasis.
    J Urol. 2017;198:1212-1214.
    PubMed     Text format    

  27. ATALA A
    Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer.
    J Urol. 2017;198:1213.
    PubMed     Text format    

  28. TANEJA SS
    Re: Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis and Response to Androgen Deprivation Therapy.
    J Urol. 2017;198:1211.
    PubMed     Text format    


    Nat Rev Urol

  29. FENNER A
    Prostate cancer: Conserved lipid synthesis drives castration resistance.
    Nat Rev Urol. 2017 Nov 14. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  30. THOMA C
    Prostate cancer: Response prediction with HSD3B1.
    Nat Rev Urol. 2017 Nov 14. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncol Rep

  31. WA Q, Li L, Lin H, Peng X, et al
    Downregulation of miR19a3p promotes invasion, migration and bone metastasis via activating TGFbeta signaling in prostate cancer.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6096.
    PubMed     Text format     Abstract available

  32. KUBO M, Satoh T, Ishiyama H, Tabata KI, et al
    Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6095.
    PubMed     Text format     Abstract available

  33. ZOU P, Yang Y, Xu X, Liu B, et al
    Silencing of vacuolar ATPase c subunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner.
    Oncol Rep. 2017 Nov 10. doi: 10.3892/or.2017.6092.
    PubMed     Text format     Abstract available


    PLoS One

  34. TAUROZZI AJ, Beekharry R, Wantoch M, Labarthe MC, et al
    Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program.
    PLoS One. 2017;12:e0188228.
    PubMed     Text format     Abstract available

  35. JEON HG, Yoo JH, Jeong BC, Seo SI, et al
    Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
    PLoS One. 2017;12:e0186026.
    PubMed     Text format     Abstract available


    Prostate

  36. COARFA C, Florentin D, Putluri N, Ding Y, et al
    Influence of the neural microenvironment on prostate cancer.
    Prostate. 2017 Nov 13. doi: 10.1002/pros.23454.
    PubMed     Text format     Abstract available

  37. KALSBEEK AMF, Chan EKF, Grogan J, Petersen DC, et al
    Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
    Prostate. 2017 Nov 14. doi: 10.1002/pros.23440.
    PubMed     Text format     Abstract available

  38. GHASHGHAEI M, Paliouras M, Heravi M, Bekerat H, et al
    Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Prostate. 2017 Nov 14. doi: 10.1002/pros.23445.
    PubMed     Text format     Abstract available

  39. FACINA CH, Campos SGP, Goncalves BF, Goes RM, et al
    Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer.
    Prostate. 2017 Nov 17. doi: 10.1002/pros.23458.
    PubMed     Text format     Abstract available


    Urology

  40. BARQAWI A, Huebner E, Krughoff K, O'Donnell CI, et al
    Prospective Outcome Analysis of the Safety and Efficacy of Partial and Complete Cryoablation in Organ-Confined Prostate Cancer.
    Urology. 2017 Nov 7. pii: S0090-4295(17)31163.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: